NYSE:AZN - AstraZeneca Stock Price, Forecast & News

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

Shares of AstraZeneca split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were issued to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

AstraZeneca plc (NYSE:AZN) posted its quarterly earnings results on Friday, February, 14th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.53 by $0.08. The firm had revenue of $6.66 billion for the quarter, compared to analysts' expectations of $6.75 billion. AstraZeneca had a net margin of 8.42% and a return on equity of 38.63%. The business's revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.58 EPS. View AstraZeneca's Earnings History.

AstraZeneca is scheduled to release their next quarterly earnings announcement on Friday, April 24th 2020. View Earnings Estimates for AstraZeneca.

12 brokers have issued 1 year price objectives for AstraZeneca's stock. Their forecasts range from $40.73 to $57.00. On average, they expect AstraZeneca's share price to reach $50.68 in the next twelve months. This suggests a possible upside of 5.9% from the stock's current price. View Analyst Price Targets for AstraZeneca.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 4 sell ratings, 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AstraZeneca.

News headlines about AZN stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AstraZeneca earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for AstraZeneca.

Some companies that are related to AstraZeneca include Abbott Laboratories (ABT), AbbVie (ABBV), Sanofi (SNY), Celgene (CELG), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Alnylam Pharmaceuticals (ALNY), ACADIA Pharmaceuticals (ACAD), The Medicines (MDCO), Amarin (AMRN), Ascendis Pharma A/S (ASND), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS) and Axsome Therapeutics (AXSM).

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), AT&T (T), AbbVie (ABBV), Bank of America (BAC), Cisco Systems (CSCO), Merck & Co., Inc. (MRK), Gilead Sciences (GILD), Intel (INTC), Micron Technology (MU) and Bristol-Myers Squibb (BMY).

AstraZeneca's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (2.02%), Jennison Associates LLC (1.40%), Bank of America Corp DE (0.35%), GQG Partners LLC (0.27%), Franklin Resources Inc. (0.21%) and Bank of Montreal Can (0.09%). View Institutional Ownership Trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Bank of America Corp DE, Marshall Wace LLP, Bank of Montreal Can, Schafer Cullen Capital Management Inc, Russell Investments Group Ltd., Charles Schwab Investment Management Inc. and Becker Capital Management Inc.. View Insider Buying and Selling for AstraZeneca.

AZN stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, GQG Partners LLC, Renaissance Technologies LLC, Jennison Associates LLC, Galibier Capital Management Ltd., Ariose Capital Management Ltd, Sectoral Asset Management Inc and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $47.85.

AstraZeneca has a market capitalization of $125.55 billion and generates $22.09 billion in revenue each year. The company earns $2.16 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.View Additional Information About AstraZeneca.